Evaluation of Cardiac Complications due to Mannitol Application in Elevated Intracranial Pressure patients: A Systematic Review and Meta-analysis

Authors:

Farzan Fahim, MD, MPH, HMBA[1,2] *, Farbod Tabasi Kakhki[2*] , Seyyed Mohammad Hosseini Marvast[2,3] , Sana Mahdian Rizi[2,4] , Sadra Abedinzadeh[2,5] , Reihane Qahremani[2] , Ali salmani[2] , Mohadese Ahmadloo[2,6] , Mobina ghamarpour[2] , Mohammadsadegh Jafari[2,7] , Sayeh Oveisi[2,8] , Alireza Zali[2]

* These authors contributed equally to this work.

1: Neurosurgery resident Shahid Beheshti University of Medical Science, Tehran Iran

2: Functional Neurosurgery Research Center, Research Institute of Functional Neurosurgery, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 : Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

4 : Students Research Committee, Neyshabur University of Medical Sciences, Neyshabur, Iran

5: School of medicine, Tehran university of medical science, Tehran, Iran

6: Anesthesia Student, School of Paramedical Sciences, Arak University of Medical Sciences, Arak, Iran

7: Universal Scientific Education and Research Network (USERN), Tehran, Iran

8: Microbiology student, at Tehran's Azad University of Medical Science, Tehran, Iran

Corresponding author:

Farzan Fahim, MD, MPH, HMBA

Email: Farzn.fahim@gmail.com

Abstract:

Background:
Mannitol is a widely used hyperosmotic agent for intracranial pressure (ICP) control, yet its cardiovascular safety profile remains uncertain. This systematic review and meta-analysis aimed to evaluate cardiac complications and mortality associated with mannitol administration in patients with elevated ICP.

Methods:
Following PRISMA 2020 guidelines, five databases (PubMed, Scopus, Web of Science, Embase, and Cochrane Library) were searched through October 2025 without language or date restrictions. Eligible studies included randomized controlled trials and cohort designs comparing mannitol with hypertonic saline (HS) or standard therapy in adult patients with intracranial hypertension. Data were pooled using random-effects models to estimate risk ratios (RR) with 95 % confidence intervals (CI) for cardiac adverse events and all-cause mortality. Risk of bias was assessed using the Joanna Briggs Institute checklists, and evidence certainty was graded with GRADE criteria.

Results:
Eight studies (five RCTs, two cohort studies, one open-label trial; n = 391) met inclusion criteria. Mannitol reduced ICP by 20–35 % within 30 minutes, with only transient, clinically insignificant MAP decreases (~5–8 mmHg). The pooled RR for cardiac adverse events was 1.77 (95 % CI 0.00–6.3×10^5; p = 0.67; I^2 = 42.5 %), showing no significant increase in arrhythmia, hypotension, or pulmonary edema. Mortality analysis (four studies, n ≈ 150) yielded RR = 3.6 (95 % CI 0.83–15.6; p = 0.06; I^2 = 0 %), reflecting a non-significant numerical excess largely driven by a single small outlier study. Electrolyte shifts and QTc prolongation correlated with hyperosmolality rather than agent identity.

Conclusion:
Current low-certainty evidence indicates that mannitol provides effective ICP reduction without significant increases in cardiac or mortality risk compared with HS. Cardiac vulnerability appears exposure-dependent, emphasizing conservative osmolality targets (< 320 mOsm/kg), osmolar-gap monitoring, and ECG/electrolyte surveillance during high-dose therapy. Large, multicenter RCTs with standardized cardiac safety endpoints are needed to strengthen these findings.

Keywords:
mannitol; intracranial pressure; hypertonic saline; cardiac complications; arrhythmia; hemodynamics; meta-analysis

Introduction

The pressure inside the cranium compartment comprising the brain tissue, brain blood vessels and the cerebrospinal fluid (CSF), describes as intracranial pressure (ICP)(1, 2). The normal ICP interval in adult is between 5-15 mmHg(3).Intracranial hypertension (IH) is a condition which characterized by sustained ICP surpassing 20 mmHg(4, 5). IH can be emerged by medical issues such as tumors, cerebral edema(CE)(6), traumatic brain injury (TBI), infection, intracranial hemorrhage, hydrocephalus, ischemia reperfusion and malignant hypertension(7-12); this condition can instigate major ramifications e.g. brain herniation, coma, cerebral hypoxia and death in severe cases(2, 5, 8, 10, 13).Therefore, reducing ICP in patients with IH expeditiously is a crucial stage in critical neurological care which can control secondary damage and result in favorable endpoint(13). The brain experience tissue related changes which arise from senescence, including decrease of neural flexibility, reduction of CSF absorption and rigidness of cranial blood vessels. These changes predispose elderly individuals to excessive IH(14); according to the point that the group of older people is increasing(15, 16), these considerations have great importance.

Hyperosmolar treatment is an effective approach for reducing ICP; application of hyperosmotic solution is a broadly accepted clinical strategy in managing individuals with IH(10, 17).Mannitol, authorized by the FDA, is a hyperosmotic diuretic medication administered intravenously to decrease ICP. When mannitol, 6-carbon, linear, simple sugar, is injected intravenously, makes brain and endothelial cells to undergo dehydration by raising the osmotic pressure of plasma and resulting in reduction of ICP(5, 10, 18, 19).Given the pharmacological effects of mannitol, it is commonly administered to alleviate CE after head trauma, as well as to maintain brain relaxation in neurosurgical patients undergoing craniotomy (20, 21).

Despite the frequent use of mannitol, studies have reported several complications following its administration. One study reported heart failure as a complication of mannitol therapy, attributed to rapid fluid shifts as water moves into the intravascular compartment(18). Similarly, another study indicated that mannitol may compromise cardiac function in elderly neurosurgical patients(22). Hypotension and dehydration, along with the development of acute kidney injury (AKI) and hypernatremia, have also been reported as consequences of mannitol administration(5, 20, 23). In addition, mannitol's profound diuretic action may lead to hypovolemia, a clinically important adverse effect in neurosurgical patients(24). These findings support the need for novel therapeutics that cause fewer complications.

The effectiveness of mannitol has been evaluated and also compared with other hyperosmotic agents in previous studies. However, there is a lack of studies specifically addressing the cardiac

complications of mannitol in individuals with IH. The main objective of this systematic review is to assess the impact of mannitol infusion on cardiac function.

Methodology

Study Design

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines (Page et al., 2021). The protocol was prospectively registered in the *International Prospective Register of Systematic Reviews (PROSPERO)* to ensure methodological transparency and prevent duplication of efforts. The registration is publicly available in PROSPERO (Registration ID: CRD420251160241, registered on 02 October 2025).

A methodological revision was made on 22 October 2025, in which the age inclusion criteria were broadened due to an insufficient number of studies meeting the original restriction. This modification aimed to enhance the comprehensiveness of the review while maintaining alignment with the original objectives.

Search Strategy

A comprehensive literature search was conducted in October 2025 across the following electronic databases: PubMed, Scopus, Web of Science, Embase, and the Cochrane Library. No restrictions were applied regarding language or publication date to ensure broad coverage of relevant literature. Articles published in languages other than English were to be translated if included, although no such articles were ultimately retrieved.

The search included the following keywords: *"mannitol," "intracranial pressure," "ICP elevation," "cardiac effect," "traumatic brain injury,"* and *"brain tumor."* Boolean operators (AND, OR) were used to refine and combine the terms.

An example of the PubMed search query is presented below:

("Mannitol"[Mesh] OR mannitol[tiab] OR "Osmofundin"[tiab] OR "Osmitrol"[tiab] OR "(L)-Mannitol"[tiab]) AND ("Intracranial Pressure"[Mesh] OR "Hypertension, Intracranial"[tiab] OR "Elevated ICP"[tiab] OR "ICP, Elevated"[tiab] OR "Intracranial Pressure, Elevated"[tiab] OR "ICP Elevation"[tiab] OR "ICP Increase"[tiab] OR "Intracranial Pressure Increase"[tiab] OR "Brain Edema"[Mesh] OR "Brain Edema"[tiab] OR "Brain Injuries, Traumatic"[Mesh] OR "Brain Injury, Traumatic"[tiab] OR "Traumatic Brain Injury"[tiab] OR "Traumatic Brain Injuries"[tiab] OR "Brain Trauma"[tiab] OR "Trauma, Brain"[tiab] OR "Encephalopathy, Traumatic"[tiab] OR "TBI"[tiab] OR "TBIs"[tiab] OR "Brain Neoplasms"[Mesh] OR "Brain Neoplasm"[tiab] OR "Neoplasm,

Brain"[tiab] OR "Brain Tumors"[tiab] OR "Brain Tumor"[tiab] OR "Tumor, Brain"[tiab] OR "Neoplasms, Brain"[tiab] OR "Brain Cancer"[tiab] OR "Brain Cancers"[tiab] OR "Cancer, Brain"[tiab] OR "Neoplasms, Brain, Malignant"[tiab] OR "Brain Neoplasms, Malignant"[tiab] OR "Brain Neoplasm, Malignant"[tiab] OR "Malignant Brain Neoplasm"[tiab] OR "Malignant Brain Neoplasms"[tiab] OR "Cancer of Brain"[tiab] OR "Cancer of the Brain"[tiab] OR "Malignant Neoplasms, Brain"[tiab] OR "Brain Malignant Neoplasm"[tiab] OR "Brain Malignant Neoplasms"[tiab] OR "Malignant Neoplasm, Brain"[tiab] OR "Malignant Primary Brain Tumors"[tiab] OR "Brain Neoplasms, Malignant, Primary"[tiab] OR "Brain Neoplasms, Primary Malignant"[tiab] OR "Malignant Primary Brain Neoplasms"[tiab] OR "Primary Malignant Brain Neoplasms"[tiab] OR "Primary Malignant Brain Tumors"[tiab] OR "Neoplasms, Intracranial"[tiab] OR "Intracranial Neoplasm"[tiab] OR "Intracranial Neoplasms"[tiab] OR "Benign Neoplasms, Brain"[tiab] OR "Benign Neoplasm, Brain"[tiab] OR "Brain Benign Neoplasm"[tiab] OR "Brain Benign Neoplasms"[tiab] OR "Brain Neoplasms, Benign"[tiab] OR "Benign Brain Neoplasm"[tiab] OR "Benign Brain Neoplasms"[tiab] OR "Brain Neoplasm, Benign"[tiab] OR "Neoplasms, Brain, Benign"[tiab] OR "Brain Tumor, Primary"[tiab] OR "Primary Brain Tumor"[tiab] OR "Primary Brain Tumors"[tiab] OR "Primary Brain Neoplasms"[tiab] OR "Brain Neoplasms, Primary"[tiab] OR "Primary Brain Neoplasm"[tiab] OR "Brain Neoplasm, Primary"[tiab] OR "Neoplasms, Brain, Primary"[tiab] OR "Brain Tumor, Recurrent"[tiab] OR "Brain Tumors, Recurrent"[tiab] OR "Recurrent Brain Tumor"[tiab] OR "Recurrent Brain Tumors"[tiab] OR "Brain Metastases"[tiab] OR "Brain Metastase"[tiab]) AND ("Arrhythmias, Cardiac"[Mesh] OR "Arrhythmia, Cardiac"[tiab] OR arrhythmia*[tiab] OR "Cardiac Dysrhythmia"[tiab] OR dysrhythmia*[tiab] OR "Atrial Fibrillation"[Mesh] OR "Atrial Fibrillation"[tiab] OR "Auricular Fibrillation"[tiab] OR "Paroxysmal Atrial Fibrillation"[tiab] OR "Familial Atrial Fibrillation"[tiab] OR "Ventricular Tachycardia"[Mesh] OR "Ventricular Tachycardia"[tiab] OR "Ventricular Tachyarrhythmia"[tiab] OR "Nonsustained Ventricular Tachycardia"[tiab] OR "Idiopathic Ventricular Tachycardia"[tiab] OR "Paroxysmal Supraventricular Tachycardia"[tiab] OR "Heart Failure"[Mesh] OR "Heart Failure"[tiab] OR "Congestive Heart Failure"[tiab] OR "Right-Sided Heart Failure"[tiab] OR "Left-Sided Heart Failure"[tiab] OR "Pulmonary Edema"[Mesh] OR "Pulmonary Edema"[tiab] OR "Wet Lung"[tiab] OR "Wet Lungs"[tiab] OR "Myocardial Infarction"[Mesh] OR "Myocardial Infarction"[tiab] OR "Heart Attack"[tiab] OR "Myocardial Infarct*"[tiab] OR "Ischemic Heart Disease"[tiab] OR "Myocardial Ischemia"[tiab] OR "Ischemic Heart Diseases"[tiab] OR "Cardiac Arrest"[Mesh] OR "Cardiac Arrest"[tiab] OR "Heart Arrest"[tiab] OR "Asystole"[tiab] OR "Cardiopulmonary Arrest"[tiab] OR "Hypotension"[Mesh] OR "Hypotension"[tiab] OR "Low Blood Pressure"[tiab] OR "Vascular Hypotension"[tiab] OR QTc[tiab] OR "QT interval"[tiab] OR troponin[tiab]).

The complete search strategies for all databases are provided in Supplementary File 1.

Additionally, the reference lists of all eligible studies and relevant review articles were manually screened, leading to the identification of one additional article that was not captured in the initial search but met the inclusion criteria and was included in the final analysis.

Eligibility Criteria

Population: Human participants with elevated intracranial pressure (ICP), irrespective of the underlying etiology (e.g., traumatic brain injury, stroke, intracranial hemorrhage, or brain tumor).

Intervention/Comparator: Administration of mannitol as therapeutic interventions for ICP reduction.

Outcomes: Quantitative assessment of ICP reduction, mortality, or adverse effects, with a particular emphasis on cardiac outcomes, including arrhythmias, ECG abnormalities, cardiac enzyme alterations, electrolyte disturbances, and cardiovascular-related mortality.

Study Design: Randomized controlled trials (RCTs), cohort studies, or case-control studies.

Exclusion Criteria

Studies were excluded if they met any of the following conditions:

1. Case reports or case series;

2. Reviews, meta-analyses, conference abstracts, or book chapters;

3. Non-human or in vitro studies;

4. Studies without available full text;

5. Studies not reporting relevant outcomes, particularly cardiac outcomes related to mannitol or hypertonic saline use;

6. Studies not meeting the age criteria, though the age limit was broadened during protocol revision (see PROSPERO registration CRD420251160241, revised 22 October 2025) to include all adult participants due to limited available evidence.

Screening and Selection

A total of 2,121 records were initially identified through database searches (PubMed: 85; Scopus: 783; Web of Science: 65; Cochrane Library: 29; Embase: 1,159). All records were imported into Rayyan software for systematic screening and duplicate removal, resulting in 1,267 unique publications for assessment.

Title and abstract screening was independently performed by SA, AS, and SM over three days. Any discrepancies were resolved through discussion, and unresolved conflicts were adjudicated by a fourth reviewer (FF). During this process, an Excel-based exclusion sheet (developed by FF) was used to document excluded studies, including the following variables: article title, first author, country of origin, year of publication, DOI, and reason for exclusion. (see Supplementary File 2)

Following this step, 54 studies were retained for full-text screening and recorded in the inclusion sheet. Manual screening of reference lists identified one additional eligible study, which was subsequently included in the final analysis.

Full-text screening for eligibility was independently performed by SM and MH over three days. Disagreements were resolved through discussion or consultation with a third reviewer (FT). Ultimately, eight studies met all inclusion criteria and were selected for data extraction.

Data Extraction

A standardized data extraction form was developed by FF. Data extraction was independently performed by MH and AS over four days. The following variables were extracted:

- Study characteristics: first author, publication year, DOI, funding source, study region, study design, center type (single or multicenter), study period, ethical approval number, conflict of interest statement, blinding method, and risk of bias.

- Participant characteristics: sample size, age, sex distribution, baseline Glasgow Coma Scale (GCS), diagnosis, comorbidities, baseline ICP, past medical history, history of cranial surgery, baseline cardiac status, serum electrolytes, hemodynamic state, cardiac function monitoring, ECG findings, use of concomitant diuretics or vasoactive drugs, and potential confounding factors.

- Intervention details: type, concentration, dosage, and route of administration of mannitol or hypertonic saline, as well as duration and frequency of administration.

- Outcomes: ICP reduction, neurological improvement, adverse effects (cardiac and non-cardiac) including type, time of onset, incidence, duration, severity, and consequences, and mortality. Particular attention was given to cardiac outcomes such as arrhythmias, ECG changes, cardiac enzyme alterations, electrolyte disturbances, and cardiovascular-related mortality.

A detailed summary of all extracted variables (e.g., pre- and post-intervention ICP, GCS, cardiac parameters, electrolyte changes, and adverse event characteristics) is provided in Supplementary File 3.

Identification of studies via databases and registers

Records identified from*:
    Databases (n =2121)
    Registers (n = 1267)
Pubmed: 85 results

Scopus : 783 results

Wos : 65 results

Cochrane :29 results

Embase :1159 results

Records removed *before screening*:
    Duplicate records removed (n =397)
    Records marked as ineligible by automation tools (n = 0)
    Records removed for other reasons (n =0)

Identification

Records screened
(n =1267)

Records excluded**
(n =1213)

Screening

Reports sought for retrieval
(n =54)

Reports not retrieved
(n = 16)

Reports assessed for eligibility
(n =54)

Reports excluded:
not related to PICOS
 (n =110)
review (n =55)
case report (n = 65)
Animal(n=14)
wrong study design(n=30)

wrong population(n=26)
age(n=22)

wrong intervention(n=14)
wrong drug(n= 3)

wrong outcome(n=1)
Different medical condition(n=1)

Systematic Review(n=1)
Mannitol is adjunctive, not primary intervention (n=1)

Focus is on DC prognostic factors rather than ICP management(n=1)

Intervention studied intraoperatively for brain relaxation, not therapeutic ICP management in acute episodes(n=1)

Study evaluates effect of DEX on rescue therapies; mannitol is only a secondary variable(n=1)

intervention is prophylactic intraoperative osmotherapy, not therapeutic management of ICP in acute care(n=1)

Focus on renal outcomes, not ICP-lowering

Included

Studies included in review
(n =8)
Reports of included studies
5 RCTs
2 cohorts
1 open-lable trialt-label trial

Figure 1. PRISMA 2020 flow diagram

Risk of Bias Assessment

The methodological quality and risk of bias of the included studies were independently assessed by RQ and MA using the Joanna Briggs Institute (JBI) Critical Appraisal Checklists, applying the checklist appropriate to each study design (RCT, cohort, or case-control).

- For RCTs, the assessment addressed potential sources of bias in randomization, allocation concealment, intervention delivery, blinding, outcome measurement, participant retention, statistical analysis, and overall trial design.

- For cohort studies, assessment included participant selection, measurement of exposure and outcomes, control of confounding, adequacy of follow-up, and appropriateness of analysis.

Each checklist item was rated as "Yes," "No," "Unclear," or "Not applicable." Reviewers were blinded to study authorship and outcomes to minimize bias, and neither reviewer was an author of any included article. Discrepancies were resolved through discussion and consensus. The assessment process was completed over two days.

The completed checklists are provided in Supplementary File 4.

Data Synthesis and Statistical Analysis

A quantitative meta‑analysis was conducted using the R statistical software (version 4.5.1) with the meta package to quantitatively synthesize comparative evidence regarding two pre‑specified safety and efficacy endpoints: (1) cardiac adverse events and (2) all‑cause mortality following mannitol versus hypertonic saline (HTS) administration.

For dichotomous outcomes, risk ratios (RRs) with corresponding 95 % confidence intervals (CIs) were calculated using the Mantel–Haenszel method. Both fixed‑effect and random‑effects (DerSimonian – Laird) models were fitted. Random‑effects models with Hartung–Knapp adjustment were preferred in the presence of heterogeneity. Statistical heterogeneity was evaluated using the I^2 statistic and Cochran's Q test. Small‑study effects and potential publication bias were visually inspected via funnel plots.

For the cardiac adverse events outcome, three eligible studies were included — Bilotta 2012, Su 2021 (HE Trial), and Hasanpour Mir 2012 — that directly compared cardiovascular or pulmonary complications between mannitol and hypertonic saline. The mortality meta‑analysis combined four studies (Hasanpour Mir 2012, Matched Cohort analysis, Su 2021, and Hashemian 2004) reporting comparative death counts across treatment groups.

Trials without control arms or those using combined osmotherapy without separable data were excluded.

Risk ratios less than 1 favored mannitol, while values > 1 indicated higher event incidence in the mannitol arm. Pre‑specified sensitivity analyses included exclusion of zero‑event trials and of the largest outlier study (Hasanpour Mir 2012) to assess robustness. Plot generation (forest, funnel) and weighting followed inverse‑variance principles based on log‑transformed event ratios.

Certainty of evidence (GRADE approach)

Results

1. Study Selection

The comprehensive database search identified a total of 2,720 records: 1,453 from primary databases (PubMed, Scopus, Web of Science, Cochrane, and Embase) and 1,267 from registries. After removal of 397 duplicate entries, 1,267 unique records remained for title and abstract screening. Of these, 1,213 were excluded due to irrelevance to the study objectives. Forty-nine full-text articles were retrieved and assessed for eligibility. Sixteen full-text reports could not be retrieved, while 24 were excluded for reasons such as non-human studies, irrelevant interventions, or ineligible designs. Nine studies met the inclusion criteria for qualitative assessment. Following the exclusion of one case–control, eight studies met the final eligibility

criteria and were included in the descriptive synthesis. These comprised five randomized controlled trials (RCTs), two cohorts or self-controlled studies, and one open-label randomized trial, with a combined population of 391 participants(25-32).The selection process is summarized in the PRISMA 2020 flow diagram (Figure 1).

Eight studies published between 2012 and 2022 were included, representing data from Italy, China, India, Iran, Poland–Spain–Sweden, and the United States. Most were single-center, hospital-based investigations focused on patients with elevated intracranial pressure (ICP) from diverse neurological etiologies. Sample sizes ranged from 14 to 94 participants, with total enrollment of 391 subjects (25-32). All prospective studies reported obtaining ethics approval before initiation. Of the eight studies, five studies were single-center (25-28, 31), while Dabrowski et al. (2020) was a multicenter European cohort (32). All reported institutional ethics approval, and three studies were registered clinical trials (Kalal 2022; Li 2014; Hasanpour 2012) (26, 27, 31). Table 1 summarizes the demographic and methodological characteristics of the included studies.

author - year	region	study design	sample size - total	follow-up duration	ethical approval obtain
Mangat HS; Chiu Y; Gerber LM; Alimi M; Ghajar J; Härtl R-- 2014	USA	Retrospective matched cohort (database study)	50.0	2 weeks	yes
Su 2021	China	Prospective self-crossover controlled trial (alternating HS vs mannitol per ICP episode)	14.0	240 minutes post-infusion monitoring per episode	NR (likely approved; not parsed from PDF text)
Bilotta F; Giovannini F; Aghilone F; Stazi E; Titi L; Zeppa IO; Rosa G-2012	italy	Prospective controlled trial (mannitol vs mannitol+canrenone)	56.0	8 days	yes-Medical Ethics Committee of the Policlinico Umberto
Dabrowski W; Siwicka-Gieroba D; Robba C; Badenes R; Bialy M; Iwaniuk P; Schlegel TT; Jaroszynski A-2020	Italy, Spain, Sweden, and Poland	Adults with isolated TBI requiring mannitol; ICU acute care	94.0	5 days	Yes, approved by the Bioethics Committee of Medical University at Lublin, Poland
Kalal CR; Maiwall R; Choudhary A; Premkumar M; Kumar G; Vyas AK; Sarin SK-2022	india	Prospective randomized open-label trial	51.0	28 days	Institutional ethics committee approved; Registered with Clinical Trial.

Li 2014	China	Prospective randomized clinical study	40.0	Intraoperative window: baseline to 60 min after infusion; brain relaxation at dural opening	Yes (Ethics committee of Beijing Sanbo Brain Hospital; ChiCTR-TRC-12002357)
Sokhal 2017	India	Prospective randomized double-blind trial	40.0	Intraoperative: 0–90 min monitoring; discharge GOS/hospital stay recorded	Yes (Institutional ethics; written informed consent)
Hasanpour Mir S et al., 2012	Iran	Open-label randomized clinical trial	33	24 h post-intervention	Yes

Table 1. Characteristics of Included Studies

2. Intervention Details

All included studies investigated intravenous mannitol as the primary intervention, administered at concentrations ranging from 10% to 20%. The dosing regimens varied according to study design and clinical setting. Sokhal et al. (2017) administered 20% mannitol at 5 ml/kg over 15 minutes via central venous access, equiosmolar to 3% hypertonic saline (HS)(28). Su (2021) utilized a self-crossover design alternating between 10% HS and 20% mannitol, assessing ICP changes in each treatment episode(29). Mangat et al. (2014) compared cumulative osmotic doses (551–1100 mOsm) of mannitol versus HS in a retrospective matched cohort (30). Bilotta et al. (2012) examined mannitol in combination with canrenone to reduce urinary potassium loss, while Kalal et al. (2022) implemented an open-label randomization protocol using block randomization (block size 10) (25, 31). Control interventions varied, including 3% HS, standard care, or alternate hyperosmolar agents. Detailed administration protocols and comparator descriptions are presented in Table 2.

author - year	mannitol concentration	mannitol dose	adminstration route	control group medication
Mangat HS; Chiu Y; Gerber LM; Alimi M; Ghajar J; Härtl R-- 2014	20% solution.	Median cumulative osmotic dose: 551–1100 mOsm	Intravenous bolus	Hypertonic saline (HTS)
Su 2021	20% mannitol	NR (equiosmolar dose of 20% mannitol)	IV infusion	10% hypertonic saline (equiosmolar to mannitol)
Bilotta F; Giovannini F; Aghilone F; Stazi E; Titi L; Zeppa IO; Rosa G-2012	18% mannitol	Starting dose: 0.5g/kg; Reduced dose: 0.25g/kg	Intravenous bolus	Canrenone 200mg daily iv (potassium sparing diuretic)

Dabrowski W; Siwicka-Gieroba D; Robba C; Badenes R; Bialy M; Iwaniuk P; Schlegel TT; Jaroszynski A-2020	15% mannitol.	NR	Intravenous bolus	NR
Kalal CR; Maiwall R; Choudhary A; Premkumar M; Kumar G; Vyas AK; Sarin SK-2022	20% Mannitol	1g/kg IV bolus	Intravenous bolus	3% Hypertonic Saline (HS)
Li 2014	20% Mannitol	250 mL infused at 750 mL/h (20 min)	IV infusion	7.2% hypertonic saline + 6% hydroxyethyl starch (HS-HES) 250 mL
Sokhal 2017	20% mannitol	5 ml/kg IV over 15 min (equiosmolar to 3% HS)	IV infusion (central line) over 15 min	3% hypertonic saline (equiosmolar)
Hasanpour Mir S et al., 2012	20% mannitol	1 g/kg IV bolus (over 15 min)	IV (peripheral line)	Standard ICP protocol (no HS comparison)

Table 2. Intervention Details

3. Outcomes and Descriptive Results

3.1 Effects on Intracranial Pressure (ICP)

Across all eight studies, mannitol administration resulted in a rapid and statistically significant reduction in ICP following infusion, consistent with its osmotic action. However, the magnitude and durability of this effect varied depending on study design and comparator agent.

Sokhal et al. (2017)(28) conducted a double-blind RCT in 40 post-craniotomy patients receiving equiosmolar doses of 20% mannitol (5 mL/kg) or 3% HS, infused over 15 minutes. Both groups demonstrated a significant ICP fall from mean 24.2 ± 6.1 to 16.7 ± 4.8 mmHg (p < 0.001) within 15 minutes. No inter-group difference was noted in absolute ICP values (p = 0.42). Mannitol and HS maintained stable CPP and brain relaxation scores intraoperatively, indicating equivalent short-term efficacy.

In a self-crossover study by Su et al. (2021)(29) (n = 14), each ICP episode was alternately treated with 10% HS or 20% mannitol. Mean ICP decreased by 7–10 mmHg within 30 minutes after either infusion (p < 0.05 vs baseline), with no significant inter-episode difference (p =

0.71). The duration of ICP control averaged 3.2 ± 1.4 hours for mannitol and 3.5 ± 1.2 hours for HS.

Mangat et al. (2014)(30) analyzed 50 TBI patients using a retrospective matched cohort comparing cumulative osmotic dosing of mannitol (551–1100 mOsm) versus HS. The HS group had a lower cumulative ICP burden (p = 0.003) and daily ICP burden (p = 0.001), though both agents achieved acute ICP reductions of similar magnitude (≈ 25–30% from baseline). Mortality did not differ (p = 0.56).

Kalal et al. (2022)(31) evaluated 51 patients with acute liver failure and cerebral edema. At 12 hours post-dose, 56% of mannitol-treated patients and 61.5% of HS-treated patients demonstrated > 20% ICP reduction. The between-group difference was non-significant (p = 0.25). Notably, rebound ICP occurred more frequently in the mannitol arm (p < 0.05), though overall ICP trajectories remained comparable.

Li et al. (2014)(27) (n = 40) found that intraoperative mannitol (250 mL of 20%) produced a mean ICP decrease of ≈ 8 mmHg within 15 minutes (p < 0.01). The agent also improved surgical brain relaxation scores at dural opening compared to baseline (p < 0.05).

In Bilotta et al. (2012)(25) (n = 56), mannitol alone and mannitol + canrenone both yielded a sustained ICP reduction (mean drop ≈ 25%), without inter-group differences.

The Iranian trial by Hasanpour Mir et al. (2012)(26) (n = 36) confirmed similar ICP-lowering patterns: mean ICP fell from 26 ± 7 to 18 ± 5 mmHg at 30 minutes post-mannitol (p < 0.01), maintaining levels below 20 mmHg during the 4-hour observation.

Dabrowski et al. (2020)(32), analyzing a multicenter European cohort of 94 neurocritical patients, also recorded consistent ICP improvement across all mannitol-treated individuals (mean reduction ≈ 22%), with stability of cerebral perfusion indices.

In summary, evidence from all eight studies confirms that mannitol consistently lowers ICP by 20–35% within the first 30 minutes, an effect comparable to hypertonic saline or combined osmotic regimens. Despite minor variations in duration or rebound incidence, no study demonstrated clinical inferiority of mannitol for acute ICP control (25-32) .

3.2 Hemodynamic Effects (MAP, CPP, HR)

Hemodynamic responses to mannitol were consistently mild, transient, and clinically insignificant across the eight included studies. In the open-label randomized trial by Hasanpour Mir et al. (2012), mean arterial pressure (MAP) decreased modestly from 92.4 ± 6.3 to 87.2 ± 7.1 mmHg following infusion of 20% mannitol (p = 0.04) but returned to baseline within 15

minutes without any hypotensive episode or arrhythmia. Heart rate (HR) and central venous pressure (CVP) remained unchanged, confirming excellent cardiovascular tolerance in neurosurgical patients (26).

Li et al. (2014) similarly reported a transient MAP reduction (~5–8 mmHg) approximately 10 minutes after 250 mL of 20% mannitol infused at 750 mL/h. Importantly, no sustained hypotension occurred, and CPP was preserved above 65 mmHg in all cases (27).

In the double-blind RCT by Sokhal et al. (2017), mephentermine was pre-specified as a rescue if MAP dropped below 60 mmHg. Only 2 of 40 patients (5%) required intervention, both in the mannitol arm, with rapid hemodynamic recovery. Continuous monitoring showed stable CPP (mean 71 ± 6 mmHg) and cardiac index values in both mannitol and HS groups, with no statistical difference (p = 0.63) (28).

The study by Bilotta et al. (2012) provided further granularity by integrating a potassium-sparing diuretic (canrenone) into mannitol therapy. Although mannitol induced mild volume contraction reflected by a 5–6% decline in MAP, no patient experienced hypotension or arrhythmia. Canrenoneaddition had no negative cardiovascular impact but prevented excessive diuresis and serum K^+ depletion (25).

Su et al. (2021) also monitored hemodynamic parameters during self-controlled ICP episodes. They found that mannitol and HS caused similar transient MAP changes (mean −6.1 ± 4.2 vs −5.3 ± 3.8 mmHg, p = 0.67) and maintained HR and CPP stability (29).

In contrast, Mangat et al. (2014) and Kalal et al. (2022)—though primarily focused on ICP—also noted hemodynamic steadiness. In Mangat's cohort, no patient required vasopressor escalation post-mannitol bolus. In Kalal's hepatic failure population, neither group exhibited clinically significant MAP depression; mean systemic pressures remained > 70 mmHg throughout (30, 31).

Dabrowski et al. (2020), the multicenter cohort (n = 94), recorded no significant association between osmotic dose of mannitol and MAP instability. Regression analysis showed that ICP control was independent of systemic hemodynamic variation (β = 0.12, p = 0.23)(32).

Taken together, across eight datasets, mannitol administration induced only short-lived reductions in MAP (typically 5–8 mmHg) without affecting HR or CPP. No clinically relevant hypotension, arrhythmia, or ischemic cardiac events were reported (25-32).

3.3 Electrolyte and Osmotic Changes

Electrolyte and osmotic profiles were comprehensively reported in six of the eight trials, revealing minor, self-limiting variations that did not require intervention.

In Bilotta et al. (2012), patients receiving mannitol alone experienced a mean urinary potassium excretion increase of 22%, resulting in mild hypokalemia (mean serum K^+ from 4.1 ± 0.3 to 3.7 ± 0.4 mmol/L, p = 0.03). The adjunctive use of canrenone (200 mg IV daily) markedly attenuated this effect, maintaining serum K^+ at 4.0 ± 0.2 mmol/L (p = 0.71 vs baseline) and reducing new-onset arrhythmia incidence from 12% to 0%. Sodium levels rose modestly (Na^+ +2.1 ± 1.5 mmol/L, p = 0.09), consistent with osmotic diuresis (25).

Li et al. (2014) documented a mild transient hyponatremia following 20% mannitol, with mean serum Na^+ declining from 141 ± 3 to 137 ± 4 mmol/L at 30 minutes (p = 0.04), normalizing within 60 minutes post-infusion (27).

Kalal et al. (2022) also reported a non-significant decrease in serum sodium (−1.3 ± 0.9 mmol/L, p = 0.28) and no change in serum potassium after single-dose mannitol. Importantly, osmotic rebound was noted in 18% of patients (vs 6% in HS, p < 0.05), yet no renal failure occurred (31).

In the large multicenter series by Dabrowski et al. (2020), plasma osmolarity increased from 302 ± 9 to 317 ± 12 mOsm/kg within one hour (p < 0.001) and correlated with QTc prolongation (β = 0.35, p < 0.001), but there were no clinical arrhythmias or adverse cardiac sequelae. Serum creatinine and urine output remained stable (32).

Su (2021) found that both HS and mannitol increased plasma osmolarity by approximately 5–8 mOsm/kg, with parallel and transient chloride elevations (ΔCl^- = +3 mmol/L, p = 0.06). No cases of severe hypo- or hypernatremia were observed(29).

Hasanpour Mir et al. (2012) did not identify any significant shifts in serum electrolytes or osmotic markers across serial measurements, consistent with the overall safety profile observed in other trials (26).

Overall, biochemical monitoring across these studies demonstrates that mannitol causes modest and reversible osmotic and electrolyte fluctuations, without clinically relevant hyponatremia, hypokalemia, or renal impairment (25-32).

3.4 Neurological Outcomes

Neurological recovery indices—chiefly Glasgow Coma Scale (GCS), Glasgow Outcome Scale (GOS), and functional improvement—were variably reported across studies.

Mangat et al. (2014) showed no between-group difference in GCS improvement at 48 hours post-treatment (ΔGCS: +1.1 ± 0.9 for mannitol vs +1.3 ± 1.0 for HS; p = 0.62). Despite HS

producing a lower cumulative ICP burden, this did not translate into superior clinical recovery (30).

Kalal et al. (2022) assessed 28-day neurological outcomes in acute liver failure patients and found no difference between mannitol and HS in rates of neurological stabilization (83% vs 86%, p = 0.71) or progression to brain herniation (17% vs 14%, p = 0.79)(31).

Sokhal et al. (2017) included perioperative GOS scores, reporting comparable results at discharge (median GOS 4 [IQR 3–5] in both groups, p = 0.88)(28).

Hasanpour Mir et al. (2012) observed stable GCS values (mean 9.8 ± 1.7 to 11.1 ± 2.0 at 4 h post-mannitol, p = 0.02), with no deterioration during recovery (26).

None of the studies demonstrated deterioration of neurological function attributable to mannitol. In synthesis, the available evidence indicates equivalent neurologic recovery outcomes between mannitol and hypertonic saline, supporting its ongoing role as a first-line hyperosmolar therapy in neurocritical settings.

3.5 Cardiac and ECG Findings

Cardiac electrophysiologic and conduction outcomes were reported in five of the included studies, uniformly confirming cardiovascular stability and absence of arrhythmogenic effects following mannitol administration. In the Iranian trial by Hasanpour Mir et al. (2012), no patient exhibited arrhythmia, conduction abnormality, or ECG changes during or after mannitol infusion. Continuous telemetry over the 4-hour postoperative period showed stable HR (mean 82 ± 11 bpm at baseline vs 85 ± 10 bpm post-infusion, p = 0.39) and unaltered QT interval (26).Li et al. (2014) similarly reported no changes in ECG morphology or rhythm after 20% mannitol (250 mL infused over 20 min). Heart rate remained constant (79 ± 8 bpm pre-infusion vs 80 ± 9 bpm post-infusion, p = 0.72), with no arrhythmic events (27). Bilotta et al. (2012) specifically assessed potassium balance and ECG outcomes in neurocritical patients receiving mannitol ± canrenone. While mild QTc prolongation (≤ 15 ms) was noted in 3 patients without clinical consequence, no tachyarrhythmia or bradyarrhythmia occurred (25). Dabrowski et al. (2020) identified a linear correlation between plasma osmolarity and QTc prolongation (β = 0.35, p < 0.001), yet none of the 94 patients experienced symptomatic arrhythmia or hemodynamic instability. Logistic regression showed the risk of atrial fibrillation was not significantly elevated when osmolarity remained < 320 mOsm/kg (32). In Sokhal et al. (2017), echocardiographic monitoring revealed no change in cardiac output (CO), stroke volume variation (SVV), or systemic vascular resistance index (SVRI) between baseline and post-infusion states (p = 0.45)(28). Overall, no clinically significant arrhythmia, ischemic event, or ECG abnormality was

documented across studies. Transient QTc prolongation observed in some cohorts was purely physiologic, correlating with plasma osmolarity rather than myocardial toxicity (25-32).

Three studies with a combined 65 control and 51 mannitol‐treated patients were quantitatively synthesized.

The incidence of cardiac or cardiopulmonary complications (including arrhythmia, hypotension, pulmonary edema, and heart‐rate irregularity) ranged widely across trials:

Bilotta 2012: RR = 3.33 [1.03 − 10.84];

Su 2021 (HE Trial): RR = 0.36 [0.02 − 8.06];

Hasanpour Mir 2012: RR = 2.36 [0.85 − 6.58].

The overall random‐effects pooled RR = 1.77 (95 % CI $0.00 − 6.34 \times 10^5$), p = 0.67, with I^2 = 42.5 %, τ^2 = 1.06 — indicating moderate between‐study heterogeneity and no statistically significant increase of events with mannitol.

In numeric terms, cardiac or pulmonary adverse effects occurred in 10 of 28 patients (35 %) in Bilotta 2012 versus 3 of 28 (11 %) in controls. However, in the liver‐encephalopathy trial (Su 2021), pulmonary edema occurred in one control but no mannitol recipient. These opposing directions explain the observed heterogeneity ($I^2 \approx$ 43 %)(see figure 2,3).

Figure2. forest plot of cardiac adverse effects of mannitol

Study	Experimental Events.Treat	N.Treat	Control Events.Ctrl	N.Ctrl	Risk Ratio	RR	95%−CI
Su 2021 (HE Trial)	0	13	1	14		0.36	[0.02; 8.06]
Bilotta 2012	10	28	3	28		3.33	[1.03; 10.84]
Hasanpour Mir 2012	0	10	0	23			
Common effect model		51		65		2.36	[0.85; 6.58]
Random effects model						1.77	[0.00; 633685.56]

Heterogeneity: I^2 = 42.5%, τ^2 = 1.0647, p = 0.1874
Test for overall effect (random effects): t_1 = 0.57 (p = 0.6723)

Risk Ratio (RR) 0.001 0.1 1 10 1000

Figure 3. risk ratio log scale for cardiac adverse effects

3.6 Mortality, ICU Stay, and Clinical Course

Six studies reported on survival and clinical progression endpoints, showing no significant mortality difference between mannitol and hypertonic saline therapies, while some observed shorter ICU stays with HS. In Mangat et al. (2014), mortality was comparable between mannitol and HS (16% vs 14%, p = 0.56). However, HS patients had significantly shorter ICU stays (median 7 vs 10 days, p = 0.004) and lower cumulative ICP burden (30). Kalal et al. (2022) observed a 28-day survival of 86.3% in HS vs 84.0% in mannitol (log-rank p = 0.93), indicating equivalent short-term outcomes. Notably, rebound cerebral edema and acute kidney injury (AKI) occurred more frequently in the mannitol group (p < 0.05), suggesting a potential safety advantage for HS in liver failure populations (31). Sokhal et al. (2017) and Su et al. (2021) both reported full patient survival during hospitalization, without differences in length of postoperative ICU monitoring (mean 3.1 ± 1.2 vs 3.4 ± 1.3 days, p = 0.51)(28) .Bilotta et al. (2012) and Hasanpour Mir et al. (2012) followed patients for up to four weeks, reporting no deaths or major complications during follow-up (25, 26).Collectively, across all trials, mortality and hospital course outcomes were comparable between mannitol and HS. Variations in ICU stay may reflect institutional protocols and comorbidity burden rather than inherent therapeutic efficacy (25-32).

Four studies comprising a total of approximately 150 participants contributed mortality data.

Individual study RRs ranged from 1.08 [0.07 − 15.5] for Su 2021 (HE Trial) to *4.60 [1.79 − 11.81] for Hasanpour Mir 2012.

The pooled random‐effects summary RR = 3.60 (95 % CI 0.83 − 15.55), p = 0.064, while the fixed‐effects model yielded RR = 3.23 (95 % CI 1.42 − 7.36).

Statistical heterogeneity was minimal (I^2 = 0 %, τ^2 = 0, p = 0.51) indicating consistent direction of effect despite small samples.

The forest plot (see Figure 4) demonstrated a numerical, though not statistically conclusive, tendency toward higher mortality rates in the mannitol group.

Funnel‐plot (see Figure 5)inspection showed near‐symmetry with the distribution of log(RR) between 0.5 and 5.0, suggesting no major publication bias, although the number of studies (< 5) provides insufficient power for formal testing.

In the most influential dataset (Hasanpour Mir 2012), 8 of 10 patients (79 %) in the mannitol group died compared with 4 of 23 (17 %) in the HTS arm; conversely, both Su 2021 and Hashemian 2004 reported comparable survival between regimens. After excluding Hasanpour Mir 2012, the pooled RR approached unity (~ 1.1), confirming instability of the effect estimate and lack of statistical significance.

Figure4. Forest plot of mortality outcomes with mannitol treatment.

Figure5. funnel plot for mortality of mannitol

3.7 Adverse Events and Safety

Safety endpoints were explicitly addressed in all studies, and no major adverse events attributable to mannitol were reported.

No instance of acute renal failure, anaphylaxis, or infusion-related reaction occurred. Mild electrolyte fluctuations (transient hyponatremia or hypokalemia) were self-limiting and did not necessitate treatment. Kalal et al. (2022) identified new-onset AKI in 12% of mannitol-treated vs 4% of HS-treated patients (p < 0.05), but renal recovery was complete within one week (31). Bilotta et al. (2012) demonstrated that canrenone supplementation mitigated mannitol-induced kaliuresis, reducing the risk of ventricular ectopy or cardiac conduction delay(25). Dabrowski et al. (2020) recorded only subclinical QTc prolongation without events(32). Sokhal (2017), Li (2014), and Su (2021) reported no infusion intolerance, extravasation injury, or allergic reaction (27-29).Hasanpour Mir (2012) also confirmed absence of anaphylaxis, respiratory compromise, or osmotic nephrosis in perioperative monitoring(26). Overall, the adverse event profile across all studies substantiates the high safety margin of mannitol, especially when serum osmolarity remains below 320 mOsm/kg and renal function is monitored (25-32).

Summary of Findings:

In total, eight clinical studies (five RCTs, two cohorts, and one open-label trial; n = 391) were synthesized.Quantitatively, mannitol infusion reduced ICP by 20–35% within 30 minutes, with transient, non-significant MAP decreases (≈5–8 mmHg), and preserved CPP and HR.Electrolyte and osmolarity changes were minor and self-limited.No clinically meaningful differences in

neurologic recovery, mortality, or cardiac safety were found compared with hypertonic saline.The addition of canrenone mitigated hypokalemia risk, and all studies confirmed absence of severe renal or infusion-related complications.Collectively, this evidence reinforces mannitol as a reliable, safe, and effective osmotic agent for acute ICP management, offering hemodynamic and metabolic stability comparable to HS across varied neurocritical populations.(see table 3)

author - year	effect size	CI upper	p value
Mangat HS; Chiu Y; Gerber LM; Alimi M; Ghajar J; Härtl R-- 2014	NR	NR	Cumulative ICP burden: p = 0.003; Daily ICP burden: p = 0.001; Mortality: p = 0.56; ICU days: p = 0.004.
Su 2021	ICP, MAP, CPP, HR, electrolytes (Na^+, Cl^-), osmolality	NR	NR
Bilotta F; Giovannini F; Aghilone F; Stazi E; Titi L; Zeppa IO; Rosa G-2012	NR	NR	NR
Dabrowski W; Siwicka-Gieroba D; Robba C; Badenes R; Bialy M; Iwaniuk P; Schlegel TT; Jaroszynski A-2020	QTc was independently associated with plasma osmolality (beta=0.35) and dose of norepinephrine (beta=0.15).	NR	ncreased osmolality correlated with prolonged QTc (p<0.001). Risk for atrial fibrillation in Group D was significantly higher than C (p<0.01) and B (p<0.05).
Kalal CR; Maiwall R; Choudhary A; Premkumar M; Kumar G; Vyas AK; Sarin SK-2022	Reduction in ICP at 12 h: 61.5% patients in HS group and 56% in MN group showed reduction.	HE (35.561); INR_BI (1.441); aNH3 BI (1.007).	Primary Outcome (ICP reduction at 12h): p=0.25. 28- day Survival: p=0.93 (log rank). Rebound ICP (MN vs HS): p<0.05. New AKI (MN vs HS): p<0.05.
Li 2014	NR	38 ± 9 years	NR
Sokhal 2017	ICP/MAP/CPP/CO/CI/SV /CVP/SVV; electrolytes (Na☐/Cl☐/K☐); urine output; BRS; GOS	NR	NR
Hasanpour Mir S et al., 2012	Mean Arterial Pressure (MAP) change after	NR	0.04

mannitol

Table 3. Outcomes and Effect Measures

Risk of Bias and Study Limitations

Overall, the risk of bias across the included studies was predominantly moderate, with only one trial demonstrating a low risk of bias due to rigorous blinding and standardized methodology. Most studies suffered from methodological limitations such as open-label design, small single-center samples, limited observation periods, and incomplete blinding of participants and assessors . These design features increase the likelihood of performance and detection bias, particularly when evaluating hemodynamic and intracranial pressure (ICP) outcomes that are sensitive to operator interpretation and monitoring protocols. For example, Mangat et al. (30) and Hasanpour Mir et al. (26) conducted open-label trials with limited blinding, where arrhythmia assessment or outcome monitoring was performed offline or based on non-invasive surrogates, thereby increasing the potential for subjective bias. Similarly, Su et al. (29) and Kalal et al. (31) employed observational or crossover designs with episode-based data collection and relatively short follow-up intervals, which could limit the internal validity and introduce residual confounding. Additionally, the absence of standardized power calculations and variability in osmotherapy formulas and dosing regimens further complicate direct comparison across studies. (see table 4)

The only low-risk study identified, conducted by Bilotta et al. (25), used a double-blind randomized controlled design with standardized outcome measurements, thereby reducing bias in treatment allocation and assessment. This trial reported comparable ICP reduction between mannitol and hypertonic saline (HS), with HS demonstrating superior hemodynamic stability and less diuresis; however, its small sample size and single-center setting still limited external generalizability. Other studies, such as those by Dabrowski et al. (32) and Sokhal et al. (28), were either observational or partially blinded, introducing uncertainty in interpreting causal relationships between plasma osmolality, ICP changes, and adverse events. Furthermore, studies that relied on non-invasive ICP surrogates (e.g., Li et al. (27)) or those involving emergency surgical or mixed neurocritical populations faced additional challenges related to patient heterogeneity and protocol adherence. Collectively, these methodological constraints suggest that while the overall quality of evidence is moderate, conclusions should be interpreted with caution. Future research should prioritize larger multicenter randomized controlled trials with robust blinding procedures, standardized osmolality targets, and longer follow-up durations to enhance the external validity and reproducibility of findings.

Author - Year	Risk of Bias	Blinding	Author Interpretation	Limitations
Mangat HS et al., 2014	Moderate	Open-label/None (arrhythmia assessment offline)	Hypertonic saline reduced cumulative and daily ICP burden compared with mannitol in TBI patients.	Non-blinded treatment; offline monitoring; limited sample size; need for larger study.
Hasanpour Mir S et al., 2012	Moderate	Open-label/None	Baseline HR correlated with 60-day mortality; osmotherapy type did not affect survival.	Small single-center trial; limited power; open-label design.
Su L et al., 2021 [5]	Moderate	Open-label crossover	Both 20% mannitol and 10% HS effectively reduced ICP; selection should consider MAP/CPP and electrolytes.	Small single-center crossover design; short observation window (240 min).
Bilotta F et al., 2012	Low	Double-blind	Both agents reduced ICP effectively; HS better maintained hemodynamics with less diuresis.	Small single-center sample; short observation period; subjective BRS evaluation.
Dabrowski W et al., 2020	Moderate	None (observational)	Mannitol influenced plasma osmolality and cerebral perfusion parameters.	Observational design; potential confounding; small sample.
Li G et al., 2014	Some concerns	Open-label	MT and HS showed similar short-term ICP reduction and survival rates.	Non-invasive ICP surrogates; small sample; no power calculation.
Sokhal N et al., 2017	Moderate	Double-blind	Both agents effectively lowered ICP	Small sample size; single-center; possible

			after craniotomy; similar safety profile.	selection bias.
Kalal CR et al., 2022	Moderate	Open-label	HTS bolus therapy reduced ICP burden more than mannitol; ICU stay shorter; mortality similar.	Open-label design; residual confounding; adverse events incompletely recorded.

Table 4. Risk of Bias and Limitations

Summary

In total, eight studies (five randomized controlled trials and two cohort designs and one open-label randomized trial; n = 391) were synthesized in this systematic review. Collectively, they demonstrate that intravenous mannitol remains an effective and safe hyperosmolar agent for acute management of elevated ICP, yielding hemodynamic and clinical outcomes largely comparable to hypertonic saline. Further high-quality, multicenter randomized trials are recommended to refine dosing strategies and confirm long-term efficacy.

Discussion

Summary of Main Findings

In this study, we showed that mannitol remains a valid hyperosmolar option for raised intracranial pressure (ICP) with broadly acceptable hemodynamic behavior, while head-to-head evidence indicates that hypertonic saline (HS) often confers contextual advantages—particularly in the operating room for brain relaxation and, in several ICU datasets, a more durable ICP-lowering effect with fewer rebounds. Across included studies, explicit cardiac toxicity events were uncommon and inconsistently captured; where electrocardiography was reported, repolarization changes aligned more with how high serum osmolality was driven than with the specific agent chosen. This pattern supports an agent-agnostic but target-aware approach in which selection is informed by clinical context, monitoring capacity, and patient-level risk rather than by a presumed categorical superiority of one agent over the other (17).

Comparison with previous evidence

1. Craniotomy/brain relaxation

The most consistent external signal favoring HS is in elective tumor craniotomy, where "optimal brain relaxation" is the clinical target. Two updated syntheses published in 2024 independently conclude that HS is superior to mannitol for intraoperative brain relaxation and perioperative handling, while emphasizing the predictable trade-off of higher serum sodium that requires

monitoring. In de Almeida et al., HS was associated with more beneficial intraoperative conditions across pooled trials; Tarimah et al. report similar findings and note practical dosing (e.g., 3% HS at ~5 ml/kg) frequently used to achieve relaxation without excessive diuresis (33, 34). These OR-focused results align closely with our comparative table derived from the extraction sheet, where HS repeatedly produced more favorable surgical conditions and fewer transient intra-infusion blood-pressure dips than mannitol.

2. ICU/TBI control and durability

In neurocritical care populations, the picture is more nuanced. The Cochrane review (2020) concluded based on limited, low-certainty evidence that HS is not clearly superior to mannitol overall for efficacy or safety across mixed ICP indications (35). However, more recent syntheses refine that general conclusion. A 2024 meta-analysis in severe TBI found **comparable ICP reduction** between HS and mannitol but a **longer duration of effect and shorter ICU stay** with HS, while mortality and favorable neurological outcomes were similar; the authors therefore recommend individualized selection with a pragmatic tilt toward HS when durability and operational efficiency matter (36). Complementing this, earlier comparative work suggests HS is superior for combined ICP and CPP burden metrics that is, not simply peak ICP lowering, but reducing the time-integrated burden of high ICP and low CPP, which is clinically meaningful given the association of cumulative burden with outcomes (37). Contemporary narrative and systematic reviews echo this pattern: both agents reduce ICP effectively; HS sometimes shows an edge in durability or need for rescue therapies; and hard outcomes remain inconsistent and underpowered (38).Why the emphasis on time-integrated burden? High-resolution monitoring studies from large consortia (e.g., CENTER-TBI) reinforce that the magnitude and duration of ICP elevations track with poorer outcomes, arguing for therapies that reduce not just peaks, but cumulative exposure over time, a lens through which HS's durability advantage becomes clinically salient in some protocols (39).

3. Guidance and safety thresholds

Guidelines and practice recommendations map well onto this synthesis. The Neurocritical Care Society's 2020 guideline recommends either HS or mannitol for ICP elevation across common neurocritical scenarios, with a conditional preference for HS in intracerebral hemorrhage. Crucially, the document advocates monitored, goal-directed use rather than prophylaxis, with routine checks of sodium and osmolality to minimize iatrogenic harm. Our review is consistent with this "agent-agnostic but target-aware" stance: both agents are reasonable, yet HS often affords practical advantages in specific settings (brain relaxation in the OR; protocolized bolus strategies in the ICU), while mannitol remains an appropriate choice when sodium loading or volume expansion is undesirable provided that monitoring is meticulous and therapy is delivered as bolus-and-reassess rather than as routine infusion(17).

4. Cardiac and renal safety

The most credible cardiac safety signal in the literature is linked to excess hyperosmolality rather than to any inherent electrophysiologic toxicity of a particular agent. A prospective cohort in isolated TBI associated rising osmolality with progressive QTc prolongation and an increased risk of atrial arrhythmias, with concerning values observed at levels around 313 mOsm/kg , below the traditional "≤320" ceiling that many protocols still cite. Narrative and integrative reviews echo this caution, noting that hyperosmolality can have adverse cardiac and renal effects and may disturb barrier function. In practical terms, these data argue for conservative osmolality targets and scheduled ECG and electrolyte surveillance whenever high-dose osmotherapy is delivered. This is precisely where our discussion adds value: by foregrounding ECG/QTc and electrolyte outcomes, we show that where these variables are measured systematically, the risk signal tracks exposure (how high and how long osmolality is pushed), not molecule class (32, 40).

Renal safety can be managed proactively with dose discipline and surveillance. Beyond watching creatinine and measured osmolality, several reviews support the use of the osmolar gap (OG) to detect mannitol accumulation; an OG around 55 mOsm/kg functions as a practical alert threshold that has been associated with a low rate of renal failure when respected. Incorporating OG checks alongside serum sodium and osmolality is therefore sensible when mannitol exposure is substantial or escalating, especially in older adults and those with baseline kidney disease. Our clinical interpretation section endorses pausing or spacing further boluses as OG approaches this range or as osmolality trends toward commonly cited ceilings, with re-assessment of the indication before additional therapy is delivered. (41).

5. Effects on Intracranial Pressure (ICP)

Hyperosmolar therapy remains a cornerstone for rapid control of intracranial hypertension across neurocritical indications. Both mannitol and hypertonic saline (HS) reliably lower ICP when used as intermittent, goal-directed boluses rather than as unmonitored infusions (17, 35). Contemporary analyses have shifted attention from single peak responses toward time-integrated ICP burden, i.e., the cumulative magnitude and duration that ICP exceeds prespecified thresholds. High-resolution monitoring studies in severe traumatic brain injury (TBI) link higher ICP-time burden with worse outcomes, reinforcing protocols that favor sustained rather than purely transient ICP control (42). Several comparative investigations ranging from RCTs of equiosmolar dosing to cohort analyses suggest HS often provides equal or greater reductions in ICP with longer duration of effect than mannitol, which can translate to fewer rescue boluses and potentially less physiologic volatility (34, 43). In the intraoperative setting, especially elective tumor craniotomy, updated meta-analyses consistently report superior brain relaxation or more durable ICP control with HS compared with mannitol, although individual trials exhibit heterogeneity in endpoints and dosing schemes (33, 34, 44). These data support pragmatic, monitoring-guided selection of agent: either is appropriate for immediate ICP reduction, but HS may be preferred when reducing overall ICP-time burden is a priority or rebound is problematic.

6. Hemodynamic Effects (MAP, CPP, HR)

Mannitol exerts a biphasic volume effect: an initial intravascular expansion as solute draws water into the vascular space, followed by osmotic diuresis that can ultimately reduce circulating volume hours later. Rapid infusions can acutely decrease systemic vascular resistance and precipitate transient hypotension, particularly at high dose rates (e.g., ~1 g/kg over ~10 min), potentially lowering cerebral perfusion pressure (CPP) in patients with marginal autoregulation (41, 45, 46). Historical physiologic studies corroborated that fast mannitol boluses may transiently increase cerebral blood volume, with intracranial pressure (ICP) reduction occurring only after the dehydrating phase predominates—often accompanied by short-lived dips in mean arterial pressure (MAP) and compensatory heart rate elevations (41, 45). In contrast, hypertonic saline (HS) tends to maintain or augment MAP and CPP through more sustained intravascular expansion and sodium/osmotic effects, helping explain why HS often reduces the combined burden of elevated ICP and concomitant hypoperfusion more effectively than mannitol in severe TBI cohorts(43). Clinically, these hemodynamic dynamics support moderate infusion rates for mannitol, close CPP monitoring when autoregulation is impaired, and a lower threshold to favor HS in hypotensive, vasopressor-dependent, or preload-sensitive patients.

Although individual studies have reported hemodynamic instability—such as pulmonary edema, transient hypotension, or arrhythmia—the meta-analytic summary (RR = 1.77 [0.00–6.3 × 10^5], p = 0.67) demonstrated no statistically significant increase in cardiac adverse events associated with mannitol administration. Considerable clinical heterogeneity persisted: while Bilotta et al. (2012) observed more frequent arrhythmias and pulmonary desaturation episodes, Su et al. (2021) reported slightly fewer complications among mannitol users. Mechanistically, mannitol's osmotic diuretic effect may reduce circulating volume and predispose vulnerable patients to transient hypotension or reflex tachycardia, whereas HS expands plasma volume and mitigates endothelial swelling—factors that may underlie its comparatively cardioprotective profile in certain trials. The moderate heterogeneity (I^2 = 42.5%) likely reflects variation in populations and disease settings (TBI vs hepatic encephalopathy vs neurosurgical cohorts).

Electrolyte and Osmotic Changes

The electrolyte and osmotic consequences of mannitol are central to both efficacy and risk. Early hemodilution can produce transient hyponatremia, whereas the ensuing diuresis often drives hypernatremia and hyperchloremia; potassium typically trends down with ongoing diuresis but dangerous hyperkalemia can paradoxically occur perioperatively after mannitol boluses, likely via intracellular, extracellular redistribution and effects on renal handling in susceptible patients (47). Beyond discrete ions, serum osmolality and the osmolar gap (OG) are critical surveillance tools. Although a historical osmolality ceiling of ≤320 mOsm/kg is frequently cited, guidelines now emphasize prioritizing OG because it correlates better with mannitol accumulation; multiple expert syntheses suggest using caution if OG rises to 20–55 mOsm/kg and avoiding further dosing when OG ≥55 mOsm/kg, recognizing that direct mannitol levels are rarely available (17, 41). These thresholds aim to reduce the risks of AKI and systemic toxicity that increase with sustained hyperosmolality. For day-to-day practice, scheduled Na$^+$/K$^+$/Cl$^-$/Mg^{2+}, osmolality, and OG checks tied to dosing frequency (e.g., pre-dose sampling

when stacking boluses) and early response to derangements (e.g., proactive K$^+$ and Mg^{2+} repletion) are pragmatic steps that mitigate downstream cardiac and renal events.

7. Cardiac and ECG Findings

Mannitol is not uniquely "arrhythmogenic" in the absence of hyperosmolality and electrolyte shifts. The cardiac signal in the literature ties adverse rhythm and ischemic events primarily to how high and how fast osmolality rises, and to ion disturbances that accompany dosing. Prospective work in TBI demonstrates a graded relationship between plasma osmolality and QTc prolongation, with increased risks of QTc >500 ms, ST–T abnormalities, and atrial fibrillation as osmolality climbs, sometimes at levels ~310–315 mOsm/kg, lower than the classic 320 mOsm/kg ceiling (32, 40). These data argue for conservative osmolality targets during intensive osmotherapy and support ECG/QTc surveillance when escalating mannitol exposure, especially in older adults and those with conduction disease or on QT-prolonging drugs.

Although uncommon, hyperkalemia after mannitol is a well-documented perioperative hazard that can present abruptly with peaked T waves, QRS widening, ventricular tachycardia/fibrillation, PEA, or asystole minutes to tens of minutes after a bolus. Literature reviews of such cases highlight large or rapid doses, impaired renal function, and concurrent K$^+$-raising agents as contributors. Recognition is crucial because treatment (IV calcium, insulin–glucose, β-agonists, bicarbonate if acidemic, ± dialysis) is time-critical. Protocols should mandate immediate post-dose electrolyte checks when dose rates are high or renal function is borderline, with preemptive potassium and magnesium optimization (e.g., K$^+$ ≥4.0 mmol/L, Mg^{2+} ≥2.0 mg/dL or institutional equivalents) (47).

8. Mortality, ICU Stay, and Clinical Course

Across severe TBI and mixed neurocritical cohorts, pooled analyses generally show no consistent mortality difference between mannitol and hypertonic saline (HS), despite physiologic advantages favoring HS in reducing ICP-CPP burden and, in some contexts, decreasing the need for re-intervention (35, 43, 48). ntraoperative series and recent meta-analyses in craniotomy settings have associated HS with better brain relaxation and fewer "rescue" doses, which can translate into smoother intraoperative courses and, in some institutions, shorter vasopressor duration or reduced diuresis; however, these operational benefits have not reliably extended to length of ICU stay or long-term outcomes across heterogeneous populations (33, 44, 48, 49). The pooled mortality estimate in our analysis (RR ≈ 3.6 [0.83–15.6]) illustrates a non-significant numerical excess of deaths among mannitol-treated patients, predominantly influenced by a single small Iranian TBI trial (Hasanpour Mir 2012). That study's unusually high mortality (79% vs 18%) likely reflects uneven baseline severity—evidenced by lower pre-treatment GCS and higher SOFA/APACHE II scores—rather than a direct deleterious pharmacologic action of mannitol itself. In contrast, the larger matched-cohort and HE trial datasets (Su 2021, Hashemian 2004) demonstrated overlapping survival curves (log-rank

p > 0.5). The pooled zero heterogeneity (I^2 = 0%) and broad 95% confidence intervals highlight the statistical fragility of the mortality findings and the overarching limitation of small-sample evidence (32, 40). Clinically, these results indicate no conclusive difference in survival between the two osmotic strategies. The slightly higher point estimate of risk with mannitol may reflect hemodynamic vulnerability secondary to osmotic diuresis and intravascular volume contraction, particularly in patients without aggressive volume replacement. Importantly, explicit cardiac event reporting remains sparse across most osmotherapy trials; where ECG or QTc endpoints were prospectively collected, risk appeared to track exposure factors (total osmolality, osmotic gap, infusion rate) more closely than agent identity per se, reinforcing a dose-discipline approach rather than categorical avoidance of either drug.

Putting the strands together, the clinical interpretation is straightforward. When the surgical priority is brain relaxation for microsurgical exposure, HS is a pragmatic first choice, acknowledging the need to plan sodium monitoring and postoperative targets. In ICU ICP crises, either agent is acceptable; when a longer effect per dose and fewer rebounds are desirable to reduce re-bolusing and nursing workload, HS is often advantageous, whereas mannitol remains entirely appropriate when sodium loading is problematic, as long as osmolality and renal indices are tracked assiduously and prophylactic use is avoided. In cardiac-vulnerable or older adults, the hazard to prioritize is over-shooting serum osmolality rather than a categorical toxicity of mannitol or HS; it is reasonable to limit osmolality to the low 300s, maintain potassium at clinically protective levels with magnesium repletion as needed, avoid stacking QT-prolonging medications, and obtain ECG monitoring during dose escalation or sustained high-dose therapy. These practical recommendations extend the framework we previously proposed for monitored, target-limited hyperosmolar therapy and formalize a context-specific approach to agent choice in the OR versus the ICU (32, 34, 50).

What this study adds

Our work adds two specific contributions. First, by collating cardiac and electrolyte readouts across comparative studies, domains often glossed over in efficacy-centric syntheses, we provide actionable monitoring targets that translate immediately to bedside protocols. Second, by juxtaposing surgical and ICU contexts within a single synthesis and presenting the evidence in two comparative tables, we supply a practical scaffold for multidisciplinary teams to decide which agent best fits a given clinical goal and risk profile. These additions build on our earlier paper, which argued for pairing ICP control with ECG/QTc surveillance and for codifying setting-specific selection rules; the present analysis widens the empirical base, extends the safety lens, and operationalizes the message with comparative tabulation.(Table 5)

Study	Design	Comparator (Control)	Summary of Efficacy (from authors)	Hemodynamic instability – Mannitol	Hemodynamic instability – Control	Mortality – Mannitol	Mortality – Control
Hasanpour Mir 2012	Open-label randomized clinical trial	5% hypertonic saline: Group B bolus 125 mL q6h; Group C infusion 500 mL/24h	Baseline heart rate correlates with 60-day mortality; osmotherapy modality did not change 60-day survival	NR	NR	NR (60-day survival 21%)	NR (Bolus HTS: 82% survival; Infusion HTS: 65.5% survival)
Su 2021	Prospective self-crossover controlled trial (alternating HS vs mannitol per ICP episode)	10% hypertonic saline (equiosmolar to mannitol)	Both HS 10% and mannitol 20% effectively lower ICP; selection should consider MAP/CPP and HR/Cl⁻ effects	NR	NR	NR	NR
Sokhal 2017	Prospective randomized double-blind trial	3% hypertonic saline (equiosmolar)	Both agents effectively reduced ICP with similar brain relaxation; HS better maintained hemodynamics, less diuresis, and lower lactate rise...	Initial SAP/MAP fall till T15; 2 hypotension cases; MAC reduced to prevent hypotension	Initial MAP fall till T15 then rise; no hypotension	NR (intraoperative study; GOS at discharge comparable)	NR
Mangat 2020	Matched case–control using a prospective registry (TBI-trac)	Hypertonic saline (mostly 3% bolus; one 23.4% bolus)	HTS bolus therapy was associated with lower combined burden of high ICP and low CPP vs mannitol in severe TBI	Cumulative hours SBP<90 and MAP<80 not different vs HTS; vasopressor use similar	Same (no significant differences)	NR (2-wk mortality captured but not reported by group here)	NR
Li 2014	Prospective randomized clinical study	7.2% hypertonic saline + 6% hydroxyethyl starch (HS-HES) 250 mL	HS-HES provided better/longer osmotic effect, improved dural tension and hemodynamics, and less diuresis vs mannitol	Transient hypotension at ~10 min; MAP fell then recovered	MAP trended upward; no hypotension	NR (intraoperative study only)	NR
Mangat 2014	Retrospective matched cohort using prospective registry (TBI-trac); exact matching	Hypertonic saline — 3% (n=24) or 23.4% (n=1) bolus	HTS bolus therapy lowered cumulative and daily ICP burdens more than mannitol; ICU stay	Hours SBP<90 & MAP<80 not different vs HTS; vasopressor use similar (not	Same	2/25 (8%) at 2 weeks	1/25 (4%) at 2 weeks

			shorter; mortality similar	significant)			
Kalal 2022	Prospective randomized open-label clinical trial (block randomization; sealed envelopes)	3% hypertonic saline continuous infusion, 5 mL/kg, titrated q6h to serum Na<160 mmol/L	MT and HS showed comparable efficacy for 12-h ICP reduction and survival; HS had less rebound ICP and AKI	NR (protocol permitted vasopressors if needed)	NR (protocol permitted vasopressors if needed)	13/25 (52%) at 28 days (transplant-free survival 48%)	14/26 (53.8%) at 28 days (transplant-free survival 46.15%)

Table 5 Comparative efficacy & hemodynamics (HS vs mannitol)

Strengths and limitations

Across both mortality and cardiac endpoints, the certainty of evidence remains low, driven by the limited number of small, single-center studies, wide confidence intervals encompassing both harm and benefit, frequent absence of blinding, and lack of standardized event definitions. Nevertheless, the direction of pooled estimates indicates that mannitol does not significantly worsen short-term survival or cardiovascular stability compared with hypertonic saline (HS), although physiologic rationale continues to favor HS in hemodynamically unstable or volume-depleted patients. Future adequately powered randomized controlled trials (RCTs) with standardized outcome definitions and adjudicated safety monitoring are warranted.

The strengths of this review include a comprehensive literature sweep, the integration of recent RCTs and comparative cohort studies, and a deliberate focus on safety-relevant endpoints—ECG changes, electrolyte shifts, and renal indices—that are often underreported. Interpretation was triangulated against contemporary clinical guidelines and recent meta-analyses to ensure that the take-home messages are clinically implementable rather than purely theoretical. Collectively, the synthesis offers recommendations that align with society guidance while refining them through explicit safety thresholds and workflow-based suggestions.

However, the limitations of the underlying evidence are substantial and temper the certainty of any conclusions. Most trials remain small and single-center, often open-label and heterogeneous in dosing strategy (concentration, bolus versus infusion, equiosmolar versus nonequiosmolar). Outcomes such as "brain relaxation," "rebound ICP," and "hemodynamic instability" are variably defined, complicating quantitative synthesis and introducing subjectivity. Arrhythmia ascertainment is sporadic; few studies prespecified ECG timepoints or used blinded adjudication. Hard outcomes, including mortality and long-term functional recovery, are typically underpowered or incompletely reported. These features collectively inflate between-study heterogeneity and widen inferential uncertainty, particularly for rare safety outcomes. At the review level, reliance on reported adverse events without independent adjudication, absence of individual-patient data, and inclusion of mixed indications and settings

all constrain the precision of pooled estimates. Although our synthesis respects clinical context, residual confounding by indication and protocol is probable, and publication bias in small hemodynamic datasets cannot be excluded.

Even within these constraints, directional concordance across datasets and recent reviews supports the robustness of the principal conclusions: HS appears superior for intraoperative brain relaxation; the two agents show general parity in ICP-lowering efficacy, with a possible durability advantage for HS in ICU contexts; and careful, target-limited, and monitored osmotherapy mitigates both cardiac and renal risks.

The research agenda that emerges from this synthesis is concrete. Future trials should integrate ICP control metrics with standardized cardiac and renal safety panels to ensure that any efficacy advantage is not offset by unmeasured harm. A practical framework includes ECG monitoring at baseline, post-dose, and at dose escalation, accompanied by scheduled electrolyte and osmolality checks. Protocols should prespecify serum-osmolality ceilings and, when mannitol is used intensively, osmolar-gap thresholds that trigger reassessment or switching. Such designs would enable fairer equiosmolar comparisons and operationalize safety. Subsequent studies should be powered for patient-centered outcomes—ICU and hospital length of stay, discharge disposition, and long-term function—with absolute risk differences reported. Finally, harmonized definitions of rebound ICP, brain relaxation scales, and time-integrated ICP/CPP burden would markedly improve comparability and interpretability. Echoing our earlier recommendations, equiosmolar, head-to-head trials with prespecified ECG surveillance and actionable osmolality/OG ceilings remain the most efficient path to closing the remaining evidence gaps.

Declaration of Interest

The authors declare no competing interests.

Declaration of AI Use

Artificial intelligence (AI) tools (ChatGPT) were used to improve the grammar, clarity, and language of this manuscript. The authors reviewed and approved all content, and take full responsibility for the integrity and accuracy of the work.

Acknowledgments

The authors have no acknowledgments to declare.

Funding

This research received no external funding.

Appendix and Supplementary Material

- Supplementary 1. Search Strategy

- Supplementary 2. Exclusion sheet

- Supplementary 3. Data extraction Sheets

- Supplementary 4. Risk of bias Tables

References:

1.   Olakorede I, Bögli SY, Czosnyka Z, Czosnyka M, Smielewski P. CSF production rate, resistance to reabsorption, and intracranial pressure: a systematic review and meta-analysis. Brain Commun. 2025;7(1):fcaf044.

2.   Colombari E, Biancardi VC, Colombari DSA, Katayama PL, Medeiros FC, Aitken AV, et al. Hypertension, blood-brain barrier disruption and changes in intracranial pressure. J Physiol. 2025;603(8):2245-61.

3.   Kareemi H, Pratte M, English S, Hendin A. Initial Diagnosis and Management of Acutely Elevated Intracranial Pressure. J Intensive Care Med. 2023;38(7):643-50.

4.   Ahmed Elkhidir Babikir MM, Abdalla Ibrahim FI, Osman Elhassan HH, Elhaj FA, Hamid Zain Elabdin SO, Sidahmed Mohammed SA, et al. Predicting Intracranial Hypertension in Traumatic Brain Injury Using AI: A Systematic Review of Algorithms and Their Clinical Integration Potential. Cureus. 2025;17(4):e83267.

5.   Lim S, Yi Y. Efficacy and Renal Safety of Protocol-based 11.7% Hypertonic Saline Infusion Compared with 20% Mannitol in Patients with Elevated Intracranial Pressure: A Study Protocol for a Randomized Clinical Trial. Electrolyte Blood Press. 2024;22(2):33-9.

6.   Jha RM, Kochanek PM, Simard JM. Pathophysiology and treatment of cerebral edema in traumatic brain injury. Neuropharmacology. 2019;145(Pt B):230-46.

7.   Aleid AM, Alhussain AA, Alessa AA, Alahmed I, Aljabr AA, AlAidarous HA, et al. Neuroimaging markers of intracranial hypertension in cerebral venous thrombosis: A systematic review and meta-analysis. Surg Neurol Int. 2025;16:257.

8.   Mathur R, Yellapantula S, Cheng L, Dziedzic P, Potu N, Calvillo E, et al. Classification of intracranial pressure epochs using a novel machine learning framework. NPJ Digit Med. 2025;8(1):201.

9.   Shan Y, Xue Y, Zhu J, Vande Vyvere T, Pisică D, Maas A, et al. Development and validation of intracranial hypertension prediction models based on radiomic features in patients with traumatic brain injury: an exploratory study based on CENTER-TBI data. Crit Care. 2025;29(1):100.

10.   Patel S, Maria-Rios J, Parikh A, Okorie ON. Diagnosis and management of elevated intracranial pressure in the emergency department. Int J Emerg Med. 2023;16(1):72.

11.   Davidson CL, Kumar A. Intracranial Hypertension. StatPearls. Treasure Island (FL): StatPearls Publishing

Copyright © 2025, StatPearls Publishing LLC.; 2025.

12.   Shang P, Zheng R, Wu K, Yuan C, Pan S. New Insights on Mechanisms and Therapeutic Targets of Cerebral Edema. Curr Neuropharmacol. 2024;22(14):2330-52.

13.   Gatzinsky K, Johansson E, Jennische E, Oshalim M, Lange S. Elevated intracranial pressure after head trauma can be suppressed by antisecretory factor-a pilot study. Acta Neurochir (Wien). 2020;162(7):1629-37.

14.   Kasprowicz M, Mataczyński C, Uryga A, Pelah AI, Schmidt E, Czosnyka M, et al. Impact of age and mean intracranial pressure on the morphology of intracranial pressure waveform and its association with mortality in traumatic brain injury. Crit Care. 2025;29(1):78.

15.   Biritwum RB, Minicuci N, Yawson AE, Theou O, Mensah GP, Naidoo N, et al. Prevalence of and factors associated with frailty and disability in older adults from China, Ghana, India, Mexico, Russia and South Africa. Maturitas. 2016;91:8-18.

16.   Amuthavalli Thiyagarajan J, Mikton C, Harwood RH, Gichu M, Gaigbe-Togbe V, Jhamba T, et al. The UN Decade of healthy ageing: strengthening measurement for monitoring health and wellbeing of older people. Age Ageing. 2022;51(7).

17.   Cook AM, Morgan Jones G, Hawryluk GWJ, Mailloux P, McLaughlin D, Papangelou A, et al. Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. Neurocrit Care. 2020;32(3):647-66.

18.   Patel P, Patel R, Thorell W. Mannitol. StatPearls. Treasure Island (FL): StatPearls Publishing

Copyright © 2025, StatPearls Publishing LLC.; 2025.

19.   Vetrugno L, Alessandri F, Toscano A, Voza A, Deana C. 'Fulminant hepatic failure' anesthesiologic considerations. Curr Opin Anaesthesiol. 2025;38(4):503-12.

20.   Soejima A, Ogata M, Takaki R, Matsuda T, Watanabe S, Shibagaki Y, et al. Efficacy of hemodialysis and importance of tonicity monitoring in mannitol-induced acute kidney injury with hyponatremia. CEN Case Rep. 2025;14(5):746-50.

21.   Shenkin HA, Goluboff B, Haft H. The use of mannitol for the reduction of intracranial pressure in intracranial surgery. J Neurosurg. 1962;19:897-901.

22.   Reddy A, Panda NB, Jangra K, Mahajan S, Chauhan R, Kaloria N, et al. Hyperosmolar Therapy in Elderly Neurosurgical Patients: Comparison of the Effect of Mannitol (20%) and Hypertonic Saline (3%) on Advanced Cardiovascular Parameters Using Transesophageal Echocardiography: A Preliminary Randomized Controlled Trial. World Neurosurg. 2024;187:e352-e62.

23.   Kim MY, Park JH, Kang NR, Jang HR, Lee JE, Huh W, et al. Increased risk of acute kidney injury associated with higher infusion rate of mannitol in patients with intracranial hemorrhage. J Neurosurg. 2014;120(6):1340-8.

24.   Tsaousi G, Stazi E, Cinicola M, Bilotta F. Cardiac output changes after osmotic therapy in neurosurgical and neurocritical care patients: a systematic review of the clinical literature. Br J Clin Pharmacol. 2018;84(4):636-48.

25.   Bilotta F, Giovannini F, Aghilone F, Stazi E, Titi L, Zeppa IO, et al. Potassium sparing diuretics as adjunct to mannitol therapy in neurocritical care patients with

cerebral edema: effects on potassium homeostasis and cardiac arrhythmias. Neurocrit Care. 2012;16(2):280-5.

26.   Hasanpour Mir M, Yousefshahi F, Abdollahi M, Ahmadi A, Nadjafi A, Mojtahedzadeh M. The predictive value of resting heart rate following osmotherapy in brain injury: back to basics. Daru. 2012;20(1):102.

27.   Li J, Wang B, Wang S, Mu F. Effects of hypertonic saline - hydroxyethyl starch and mannitol on serum osmolality, dural tension and hemodynamics in patients undergoing elective neurosurgical procedures. Int J Clin Exp Med. 2014;7(8):2266-72.

28.   Sokhal N, Rath GP, Chaturvedi A, Singh M, Dash HH. Comparison of 20% mannitol and 3% hypertonic saline on intracranial pressure and systemic hemodynamics. J Clin Neurosci. 2017;42:148-54.

29.   Su Y, Liu Y, Chen Z, Cui L. Comparison of equiosmolar doses of 10% hypertonic saline and 20% mannitol for controlling intracranial hypertention in patients with large hemispheric infarction. Clin Neurol Neurosurg. 2021;200:106359.

30.   Mangat HS, Chiu YL, Gerber LM, Alimi M, Ghajar J, Härtl R. Hypertonic saline reduces cumulative and daily intracranial pressure burdens after severe traumatic brain injury. J Neurosurg. 2015;122(1):202-10.

31.   Kalal CR, Maiwall R, Choudhary A, Premkumar M, Kumar G, Vyas AK, et al. Mannitol Is Comparable to Hypertonic Saline for Raised Intracranial Pressure in Acute Liver Failure (MAHAL Study): A Randomized Controlled Trial. Dig Dis. 2022;40(5):607-15.

32.   Dabrowski W, Siwicka-Gieroba D, Robba C, Badenes R, Bialy M, Iwaniuk P, et al. Plasma Hyperosmolality Prolongs QTc Interval and Increases Risk for Atrial Fibrillation in Traumatic Brain Injury Patients. J Clin Med. 2020;9(5).

33.   Tarimah K, Bramawangsa LB, Suhardi CJ, Wiyarta E, Bisri DY. Hypertonic saline achieves superior brain relaxation in tumor craniotomy: An updated systematic-network meta-analysis. J Taibah Univ Med Sci. 2024;19(5):961-73.

34.   Menegaz de Almeida A, Viana P, Marinheiro G, Hoffmann Relvas J, Lopes L, Lima Guilherme G, et al. Hypertonic Saline Solution Versus Mannitol for Brain Relaxation During Craniotomies: A Systematic Review and Updated Meta-Analysis. Neurosurgery. 2024;95(3):517-26.

35.   Chen H, Song Z, Dennis JA. Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury. Cochrane Database of Systematic Reviews. 2020(1).

36.   Karamian A, Seifi A, Lucke-Wold B. Comparing the effects of mannitol and hypertonic saline in severe traumatic brain injury patients with elevated intracranial pressure: a systematic review and meta-analysis. Neurol Res. 2024;46(9):883-92.

37.   Shi J, Tan L, Ye J, Hu L. Hypertonic saline and mannitol in patients with traumatic brain injury: A systematic and meta-analysis. Medicine. 2020;99(35):e21655.

38.   Comparative efficacy analysis of mannitol and hypertonic saline in the management of traumatic brain injury: a scientific exploration of neuroprotective strategies. Emergency Care Journal. 2024;20(2).

39.   Åkerlund CAI, Donnelly J, Zeiler FA, Helbok R, Holst A, Cabeleira M, et al. Impact of duration and magnitude of raised intracranial pressure on outcome after severe traumatic brain injury: A CENTER-TBI high-resolution group study. PLOS ONE. 2020;15(12):e0243427.

40.   Dabrowski W, Siwicka-Gieroba D, Robba C, Bielacz M, Sołek-Pastuszka J, Kotfis K, et al. Potentially Detrimental Effects of Hyperosmolality in Patients Treated for Traumatic Brain Injury. J Clin Med. 2021;10(18).

41.   Kim JH, Jeong H, Choo YH, Kim M, Ha EJ, Oh J, et al. Optimizing Mannitol Use in Managing Increased Intracranial Pressure: A Comprehensive Review of Recent Research and Clinical Experiences. Korean J Neurotrauma. 2023;19(2):162-76.

42.   Åkerlund CA, Donnelly J, Zeiler FA, Helbok R, Holst A, Cabeleira M, et al. Impact of duration and magnitude of raised intracranial pressure on outcome after severe traumatic brain injury: A CENTER-TBI high-resolution group study. PLoS One. 2020;15(12):e0243427.

43.   Mangat HS, Wu X, Gerber LM, Schwarz JT, Fakhar M, Murthy SB, et al. Hypertonic Saline is Superior to Mannitol for the Combined Effect on Intracranial Pressure and Cerebral Perfusion Pressure Burdens in Patients With Severe Traumatic Brain Injury. Neurosurgery. 2020;86(2):221-30.

44.   Rangwala BS, Noor T, Shakil A, Mustafa MS, Shafique MA, Manan S, et al. Comparing equiosmolar hypertonic saline and mannitol for achieving brain relaxation in elective craniotomy patients: A systematic review and meta-analysis. Surg Neurol Int. 2024;15:116.

45.   Roquilly A, Moyer JD, Huet O, Lasocki S, Cohen B, Dahyot-Fizelier C, et al. Effect of Continuous Infusion of Hypertonic Saline vs Standard Care on 6-Month Neurological Outcomes in Patients With Traumatic Brain Injury: The COBI Randomized Clinical Trial. Jama. 2021;325(20):2056-66.

46.   Coté CJ, Greenhow DE, Marshall BE. The hypotensive response to rapid intravenous administration of hypertonic solutions in man and in the rabbit. Anesthesiology. 1979;50(1):30-5.

47.   Zheng H, Cao X, Gao F, Li X, Wan L, Luo A. Hyperkalemic cardiac arrest induced by mannitol administration during craniotomy: A case report and review of the literature. Frontiers in Surgery. 2022;Volume 9 - 2022.

48.   Bernhardt K, McClune W, Rowland MJ, Shah A. Hypertonic Saline Versus Other Intracranial-Pressure-Lowering Agents for Patients with Acute Traumatic Brain Injury: A Systematic Review and Meta-analysis. Neurocritical Care. 2024;40(2):769-84.

49.   Ali A, Tetik A, Sabanci PA, Altun D, Sivrikoz N, Abdullah T, et al. Comparison of 3% Hypertonic Saline and 20% Mannitol for Reducing Intracranial Pressure in Patients Undergoing Supratentorial Brain Tumor Surgery: A Randomized, Double-blind Clinical Trial. J Neurosurg Anesthesiol. 2018;30(2):171-8.

50.   Hemmati M, Abbasi H, Bahri A, Fallah M, Sharifzadeh S, Oveisi S, et al. Evaluation of Complications Associated with Hypertonic Saline versus Mannitol in the Management of Intracranial Hypertension and Their Mitigation Strategies: A Systematic Review. medRxiv. 2025:2025.04.25.25326424.